Analyzing Geron’s Financial Performance
In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000.
How are IBB’s Subgroups Performing?
The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.
Exploring Geron’s Financial Performance
In fiscal 2017, Geron (GERN) generated revenues of $1 million through license fees and royalties compared with $6.1 million in fiscal 2016.
Geron: One of the Best-Performing Biotech Stocks in Past Month
Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10.
Geron Stock Rose 32% in Week Ended August 24
On August 24, Geron (GERN) stock rose ~28.78% to $5.19 from its prior day’s close of $4.03.
Understanding Geron Corp’s IMerge Trial
IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent.
A Look at Geron’s Imetelstat Research Program
IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor.
A Close Look at Geron’s Imetelstat
Geron contributes 50% of the development costs for the imetelstat trials. Imetelstat was granted fast track designation by the FDA in October 2017.
XBI on a Downward Slope, but How Steep?
On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.
Moving Averages of XBI’s Holdings Have Improved
The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.